The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Goals of care designations in advanced pancreatic cancer patients undergoing palliative chemotherapy.
 
Matthew Anaka
Stock and Other Ownership Interests - Abeona Therapeutics; Abeona Therapeutics; Abeona Therapeutics; Abeona Therapeutics; ArQule; ArQule; ArQule; ArQule; Audentes Therapeutics; Audentes Therapeutics; Audentes Therapeutics; Audentes Therapeutics; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; REGENXBIO; REGENXBIO; REGENXBIO; REGENXBIO; Spark Therapeutics; Spark Therapeutics; Spark Therapeutics; Spark Therapeutics; xenon pharma; xenon pharma; xenon pharma; xenon pharma
 
Minji Lee
No Relationships to Disclose
 
Elisa Lim
No Relationships to Disclose
 
Sunita Ghosh
No Relationships to Disclose
 
Winson Y. Cheung
No Relationships to Disclose
 
Jennifer L. Spratlin
Honoraria - Celgene; Celgene; Celgene; Celgene; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Sanofi; Sanofi; Sanofi; Sanofi
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Celgene; Celgene; Celgene; Celgene; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Sanofi; Sanofi; Sanofi; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma